Logo

OraSure Technologies: James Datin

Aug 14, 2019

OraSure Technologies has appointed James Datin to its board. He will serve as a Class III director with his initial term expiring at the company's 2021 shareholders' meeting. He will serve on OraSure's audit and compensation committees. Datin is president and CEO of BioAgilytix, a global bioanalytical contract research organization which supports the development of therapeutic biologics. Prior to that, he was executive vice president and managing director at Safeguard Scientifics. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.